<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02194361</url>
  </required_header>
  <id_info>
    <org_study_id>1147.3</org_study_id>
    <nct_id>NCT02194361</nct_id>
  </id_info>
  <brief_title>Efficacy of a Standardised Bilberry Extract in Improving the Night Vision of Healthy Volunteers</brief_title>
  <official_title>Efficacy of a Bilberry Extract Standardised to a Content of 25% Anthocyanosides in Improving the Night Vision of Healthy Volunteers: a Double-blind, Randomized, Placebo Controlled, Cross-over Trial Over 2 x 28 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to determine the Efficacy of Standardised Bilberry Extract in improving the night
      vision and to evaluate its tolerability and safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <primary_completion_date type="Actual">July 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the dark adaption of the pupil using the method of the dark adaption Goggles (DAG)</measure>
    <time_frame>From day 1 to 28 and from day 57 to day 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of the dark adaption using dark flashes</measure>
    <time_frame>From day 1 to day 28 and from day 57 to day 84</time_frame>
    <description>Pupillography (PG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of the weakest, correctly recognised contrast level</measure>
    <time_frame>From day 1 to day 28 and from day 57 to day 84</time_frame>
    <description>Mesoptometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of subjective efficacy based on a visual analogue scale (VAS) rating questionnaire</measure>
    <time_frame>pre-dose on day 1, day 28, pre-dose on day 57, day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of clinical global impression on a 5-point rating scale</measure>
    <time_frame>Days 28 and 84</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Anthocyan capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anthocyan capsules</intervention_name>
    <description>Bilberry extract capsules, 160 mg (25% anthocyanosides)</description>
    <arm_group_label>Anthocyan capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects (volunteers) with normal twilight and night vision

          -  Age 18+, young and collaborative men or women

          -  Having given their written informed consent

          -  Full visual acuity (vision 0.8 or better) according to DIN Standard condition

          -  Refraction â‰¤ +/-10.0 in the highest main step

          -  Normal intraocular pressure (10-20 mmHg)

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Epilepsy

          -  Abnormal visual acuity or abnormal morphological eye findings

          -  Glaucoma and macula degeneration

          -  Disease of the retina

          -  Consumption of anthocyan preparations during the past six months

          -  Opthalmologic pathology: cataract, visus &lt; 0.8, retinal pathology, maculopathy,
             intraocular pressure &gt; 21 mmHg, known acute or chronic eye disease, use of hard
             contact lenses, eye surgery performed within the last 12 months

          -  Any serious disorder that might interfere with his/her participation in this study and
             the evaluation of the efficacy or safety of the test drug: e.g. diabetes mellitus,
             anamnestic indications of diabetic microangiopathy or polyneuropathy, renal
             insufficiency, hepatic or metabolic dysfunction, cardiovascular disease (hypertension
             &gt; 160/100 mmHg), psychiatric disorder, myasthenia gravis, delirious state, albino

          -  Any treatment that might interfere with the evaluation of the test drug, in particular
             drugs with known influence on eye sight or adaptation (e.g. chloroquine, digitalis,
             ethambutol, chlorpromazine, benzodiazepines or phenothiazine derivatives such as
             thioridazine, periciazine, perphenazine)

          -  Known hypersensitivity to any of the ingredients of the study drug

          -  Drug and alcohol abuse

          -  Pregnancy, lactation, women of childbearing potential who do not use an established
             contraceptive

          -  Participation in another trial within the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2014</study_first_submitted>
  <study_first_submitted_qc>July 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2014</study_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

